2015 News Releases

Keyword Search
 
DateTitle  
12/15/15Dermira Added to NASDAQ Biotechnology Index
MENLO PARK, Calif., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that the company has been selected for addition to the NASDAQ Biotechnology Index® (NBI) as of December 21, 2015. The NBI is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical acc... 
 Printer Friendly Version
11/19/15Dermira Completes Patient Enrollment for Second CIMZIA(R) (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program
Enrollment Continues for Third and Final CIMZIA Phase 3 Trial in Patients With Moderate-to-Severe Plaque Psoriasis MENLO PARK, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the completion of patient enrollment for the global CIMPASI-1 clinical trial of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-severe... 
 Printer Friendly Version
11/10/15Dermira Reports Third Quarter 2015 Financial Results and Provides Corporate Update
Continued Progress for Three Late-Stage Development Programs MENLO PARK, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today reported financial results for the quarter ended September 30, 2015 and provided an update on its clinical development programs. "Our clinical development programs continue to move forward, and I am pleased to ... 
 Printer Friendly Version
10/12/15Dermira Completes Patient Enrollment for First CIMZIA(R) (Certolizumab Pegol) Phase 3 Clinical Trial in Psoriasis Program
Patient Enrollment Continues for Two Additional CIMZIA Phase 3 Trials in Patients With Moderate-to-Severe Psoriasis MENLO PARK, Calif., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the completion of patient enrollment for the global CIMPASI-2 clinical trial of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-sever... 
 Printer Friendly Version
10/07/15Dermira Presents Data From DRM01 Phase 2a Trial at European Academy of Dermatology and Venereology
Includes New Data Regarding Effects Observed at Week 4 MENLO PARK, Calif., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the presentation of data for DRM01, a novel, topical sebum inhibitor in development for the treatment of acne. Topline data from the company's Phase 2a study showed that DRM01 met all of the primary efficacy end... 
 Printer Friendly Version
09/30/15Dermira Elects Kathleen Sebelius to Board of Directors
MENLO PARK, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the election of Kathleen Sebelius, the 21st U.S. Secretary of Health and Human Services, to its board of directors. "We are honored and excited to welcome Kathleen Sebelius to Dermira's board of directors," said Tom Wiggans, chairman and chief executive officer... 
 Printer Friendly Version
09/29/15Dermira to Present Data for DRM01 Acne Program at EADV Congress 2015
Additional Analyses of Phase 2a Study to Be Presented on October 7, 2015 MENLO PARK, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that new data from its DRM01 acne program will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2015 being held October 7-11, 2015 in Copenhagen. The de... 
 Printer Friendly Version
09/10/15Skin Disposition Study Results for Dermira's DRM01 Program in Acne Presented at International Dermatology Meeting
Animal Data Demonstrate Accumulation of DRM01 in Sebaceous Glands Following Topical Administration MENLO PARK, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the presentation of new data for DRM01, a novel, topical sebum inhibitor in development for the treatment of acne. The results from a study in Yorkshire pigs demonst... 
 Printer Friendly Version
09/03/15Dermira to Present Data for DRM01 Acne Program at 45th Annual ESDR Meeting
Results of Skin Disposition Study to be Presented on September 10, 2015 MENLO PARK, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that data from its DRM01 acne program will be presented at the 45th Annual Meeting of the European Society for Dermatological Research (ESDR) being held September 9-12, 2015 in Rotterdam, Nethe... 
 Printer Friendly Version
08/13/15Dermira Reports Second Quarter 2015 Financial Results and Provides Corporate Update
Two Product Candidates Now in Phase 3 Development Approximately $104 Million in Net Proceeds From Recent Follow-on Public Offering MENLO PARK, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today reported financial results for the quarter ended June 30, 2015 and provided an update on its clinical development programs. "I am ver... 
 Printer Friendly Version
08/11/15Dermira Announces Closing of Follow-on Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
MENLO PARK, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it has closed its previously announced follow-on public offering of 5,175,000 shares of its common stock, including 675,000 shares sold upon full exercise of the underwriters' option to purchase additional shares of common stock, at a price to the public of $21... 
 Printer Friendly Version
08/05/15Dermira Prices Follow-On Public Offering of Common Stock
MENLO PARK, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the pricing of its follow-on public offering of 4,500,000 shares of its common stock at a price to the public of $21.50 per share. In addition, Dermira has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock, on... 
 Printer Friendly Version
08/04/15Dermira Commences Follow-on Public Offering of Common Stock
MENLO PARK, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it has commenced a follow-on public offering of 3,750,000 shares of its common stock. Dermira also intends to grant to the underwriters a 30-day option to purchase up to an additional 562,500 shares of its common stock, on the same terms and conditions. The offe... 
 Printer Friendly Version
08/03/15Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis
Two Identical Studies to Enroll a Combined Total of 660 Patients Topline Phase 3 Data Expected in the Second Half of 2016 Represents Dermira's Second Product Candidate in Phase 3 Development Dermira Updates 2015 Financial Guidance MENLO PARK, Calif., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the initial dosing ... 
 Printer Friendly Version
06/09/15Dermira's Phase 2a DRM01 Acne Trial Data Presented at the World Congress of Dermatology Meeting
Primary Endpoints of Changes in Lesion Counts and Improvement in Investigator's Global Assessment (IGA) Score Met With Statistical Significance MENLO PARK, Calif., June 9, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the presentation of clinical data from its successful DRM01 Phase 2a trial in patients with acne vulgaris. A poster presen... 
 Printer Friendly Version
06/02/15Dermira Announces Poster Presentation on DRM01 in Acne at World Congress of Dermatology
Safety and Efficacy Results of Phase 2a Trial to be Displayed June 9-12, 2015 MENLO PARK, Calif., June 2, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that clinical data from its DRM01 Phase 2a trial in acne will be presented at the 23rd World Congress of Dermatology, being held June 8-13, 2015, in Vancouver, Canada. The data will be pre... 
 Printer Friendly Version
05/28/15Dermira to Present at Jefferies 2015 Global Healthcare Conference
MENLO PARK, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it will present at the Jefferies 2015 Global Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 9:30 a.m. ET on Thursday, June 4, 2015 in New York. A live audio webcast and replay of the presentation w... 
 Printer Friendly Version
05/12/15Dermira Reports First Quarter 2015 Financial Results and Provides Corporate Update
Three Late-Stage Programs Continue to Progress MENLO PARK, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today reported financial results for the quarter ended March 31, 2015 and provided an update on its clinical development programs. "Dermira is currently focused on advancing its pipeline of late-stage dermatology product candidates... 
 Printer Friendly Version
04/09/15Dermira Doses First Patient in DRM01 Phase 2b Acne Trial
Study to Enroll Approximately 400 Patients With Moderate-to-Severe Acne Vulgaris MENLO PARK, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the initial dosing of the first patient in a Phase 2b dose-ranging trial for DRM01 in patients with facial acne vulgaris. The randomized, multi-center, double-blind, parallel-group, ve... 
 Printer Friendly Version
04/08/15Dermira to Present at the 14th Annual Needham Healthcare Conference
MENLO PARK, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it will present at the 14th Annual Needham Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 10:40 a.m. ET on Wednesday, April 15, 2015 in New York. A live audio webcast and replay of the presentatio... 
 Printer Friendly Version
03/25/15Dermira Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
DRM01 Phase 2b Trial in Acne to Start April 2015 Conference Call Today at 4:30 p.m. Eastern Time MENLO PARK, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today reported financial results for the quarter and year ended December 31, 2014 and provided an update on its clinical development programs and outlook for 2015. The company ... 
 Printer Friendly Version
03/23/15Clinical Data for Dermira's DRM01 Acne Program Presented at Dermatology Meeting
Phase 2a Trial Met Primary Endpoints With Statistical Significance MENLO PARK, Calif., March 23, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the presentation of clinical data from its successful DRM01 Phase 2a trial in patients with facial acne vulgaris. The primary endpoints in this trial, the changes from baseline in inflammatory and ... 
 Printer Friendly Version
03/18/15Dermira to Report Fourth Quarter and Full Year 2014 Financial Results
Management to Host Webcast and Conference Call on March 25, 2015 at 4:30 p.m. ET MENLO PARK, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated dermatology products to dermatologists and their patients, today announced that it will report fourth quarter and full year 2014 financial results after the close of U.S. financial markets on March 25, 2015. Dermira management will host a webcast... 
 Printer Friendly Version
03/12/15Dermira Announces Late-Breaking Oral Presentation on DRM01 in Acne at 2015 AAD Annual Meeting
Positive Results of Phase 2a Trial to be Presented on March 20, 2015 MENLO PARK, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that clinical data from its DRM01 Phase 2a trial in acne will be presented at the Late-Breaking Research in Dermatology Forums during the American Academy of Dermatology (AAD) Annual Meeting bein... 
 Printer Friendly Version
02/05/15Dermira Announces Positive Phase 2b Results for DRM04 in Patients With Hyperhidrosis
Phase 3 Program Expected to Start in Second Half of 2015 MENLO PARK, Calif., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced positive Phase 2b study results for DRM04, its proprietary topical anticholinergic product, in patients with axillary hyperhidrosis, or excessive underarm sweating. Based on the results of this study (DRM04-HH... 
 Printer Friendly Version
01/29/15Dermira to Present at the 2015 Leerink Global Healthcare Conference
MENLO PARK, Calif., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it will present at the 2015 Leerink Global Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 2:15 p.m. ET on Thursday, February 12, 2015, at The Waldorf Astoria Hotel in New York. A live audio webcas... 
 Printer Friendly Version
01/08/15Dermira and UCB Announce Start of Phase 3 Program for CIMZIA(R) (certolizumab pegol) in Psoriasis
Phase 3 program aims to address patient need for alternative treatment options in moderate-to-severe psoriasis   Program includes the first Phase 3 study in psoriasis comparing two anti-TNFs   Based on current enrollment projections, top-line data from these studies are expected in 2017 MENLO PARK, Calif., and BRUSSELS, Belgium, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medic... 
 Printer Friendly Version